

Expert opinion on the management of infections in the diabetic foot

B. A. Lipsky^{1*}
E. J. G. Peters²
E. Senneville³
A. R. Berendt⁴
J. M. Embil⁵
L. A. Lavery⁶
V. Urbančič-Rovan⁷
W. J. Jeffcoate⁸

¹VA Puget Sound Health Care System, University of Washington, Seattle, WA, USA

²VU University Medical Centre, Amsterdam, The Netherlands

³Gustave Dron Hospital, Tourcoing, France

⁴Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Trust, Oxford, UK

⁵University of Manitoba, Winnipeg, Manitoba, Canada

⁶University of Texas Southwestern Medical Center and Parkland Hospital, Dallas, TX, USA

⁷University Medical Centre, Ljubljana, Slovenia

⁸Nottingham University Hospitals Trust, Nottingham, UK

*Correspondence to: B. A. Lipsky, University of Washington, Director Primary Care Clinic, VA Puget Sound, VA Puget Sound System, 1660 South Columbian Way (S-123-GMS), Seattle, WA 98108, USA.
E-mail: dblipsky@hotmail.com

Summary

This update of the International Working Group on the Diabetic Foot incorporates some information from a related review of diabetic foot osteomyelitis (DFO) and a systematic review of the management of infection of the diabetic foot. The pathophysiology of these infections is now well understood, and there is a validated system for classifying the severity of infections based on their clinical findings. Diagnosing osteomyelitis remains difficult, but several recent publications have clarified the role of clinical, laboratory and imaging tests. Magnetic resonance imaging has emerged as the most accurate means of diagnosing bone infection, but bone biopsy for culture and histopathology remains the criterion standard. Determining the organisms responsible for a diabetic foot infection via culture of appropriately collected tissue specimens enables clinicians to make optimal antibiotic choices based on culture and sensitivity results. In addition to culture-directed antibiotic therapy, most infections require some surgical intervention, ranging from minor debridement to major resection, amputation or revascularization. Clinicians must also provide proper wound care to ensure healing of the wound. Various adjunctive therapies may benefit some patients, but the data supporting them are weak. If properly treated, most diabetic foot infections can be cured. Providers practising in developing countries, and their patients, face especially challenging situations. Copyright © 2012 John Wiley & Sons, Ltd.

Keywords diabetes mellitus; diabetic foot; infection; osteomyelitis; antibiotics; surgery; systematic review

Introduction

This report from the expert panel on infectious diseases of the International Working Group on the Diabetic Foot (IWGDF) is an update of the one published in 2004 [1], incorporating some information from a related IWGDF 2008 publication on osteomyelitis [2] and from the concurrently published 'Systematic Review of the Effectiveness of Interventions in the Management of Infection in the Diabetic Foot' [3]. Our intention is to present a brief overview to assist clinicians worldwide in diagnosing and treating foot infections in persons with diabetes. Separately, we have proposed 'Specific Guidelines on the Management of Diabetic Foot Infections', also published concurrently in this journal.

The development of a foot infection is associated with substantial morbidity, including discomfort, healthcare provider visits, antibiotic therapy, wound care and often surgical procedures. Furthermore, foot infection is now the most frequent diabetic complication requiring hospitalization and the most common precipitating event leading to lower extremity amputation [4–6]. Managing infection requires careful attention to properly diagnosing the condition,

Received: 12 October 2011
Accepted: 12 October 2011

obtaining specimens for culture, selecting empirical and definitive antimicrobial therapy, determining when surgical interventions are needed and caring for the wound. A systematic and, to the extent possible, evidence-based approach to diabetic foot infections (DFIs) should result in better outcomes.

Pathophysiology

In persons with diabetes, foot infection is a common problem. Infection is best defined as invasion and multiplication of microorganisms in host tissues that induces a host inflammatory response, usually followed by tissue destruction. DFI is defined clinically as a soft tissue or bone infection anywhere below the malleoli. These infections usually occur in a site of skin trauma or ulceration [7]. Peripheral neuropathy is the main factor leading to skin breaks and ulcerations, which then become colonized with skin flora and ultimately infected. Foot ischemia, related to peripheral arterial disease, is also common in patients with a DFI; while rarely the primary cause of foot wounds, the presence of limb ischemia increases the risk of a wound becoming infected [8] and adversely affects the outcome of infection [9]. Factors that predispose to foot infection include having a wound that is deep, long-standing or recurrent, ill-defined diabetes-related immunological perturbations and chronic renal failure [8,10,11]. While most DFIs are relatively superficial at presentation, microorganisms can spread contiguously to subcutaneous tissues, including fascia, tendons, muscle, joints and bone. The anatomy of the foot, which is divided into several rigid but intercommunicating

compartments, fosters proximal spread of infection. When infection-induced pressure in a compartment exceeds capillary pressure, ischemic necrosis may ensue [12,13]. Systemic symptoms (e.g. feverishness, chills), marked leukocytosis or major metabolic disturbances are uncommon in patients with a DFI, but their presence denotes a more severe, potentially limb (or even life) threatening infection [14,15]. If not diagnosed and properly treated, DFIs tend to progress, sometimes rapidly.

Classification

The clinician must first diagnose the presence of a DFI and then should classify the infection's severity. Over the past three decades, investigators have proposed many classification schemes for diabetic foot wounds. Most of these take into account the size and depth of the ulcer and the presence or absence of gangrene, neuropathy or arterial insufficiency. While several include the presence or absence of 'infection' (rarely defined), only two (nearly identical) schemes proposed by the Infectious Diseases Society of America and the IWGDF (Table 1) describe how to define both the presence and severity of infection [16].

Diagnosis

Soft tissue infection

Because all skin wounds harbour microorganisms, their mere presence, even if they are virulent species, cannot

Table 1. The classification systems for defining the presence and severity of an infection of the foot in a person with diabetes developed by the Infectious Diseases Society of America (IDSA) and the International Working Group on the Diabetic Foot (IWGDF)

Clinical classification of infection (IDSA), with definitions	IWGDF grade (IDSA classification)
<i>Uninfected:</i> No systemic or local symptoms or signs of infection	1 (uninfected)
<i>Infected:</i> – At least two of the following items are present: • Local swelling or induration • Erythema >0.5 cm ¹ around the ulcer • Local tenderness or pain • Local warmth • Purulent discharge – Other causes of an inflammatory response of the skin should be excluded (e.g. trauma, gout, acute Charcot neuro-osteopathy, fracture, thrombosis, venous stasis)	
– Infection involving the skin or subcutaneous tissue only (without involvement of deeper tissues and without systemic signs as described below) – Any erythema present extends <2 cm ¹ around the wound – No systemic signs or symptoms of infection (see below)	2 (mild infection)
– Infection involving structures deeper than skin and subcutaneous tissues (e.g. bone, joint, tendon) or erythema extending >2 cm ¹ from the wound margin – No systemic signs or symptoms of infection (see below)	3 (moderate infection)
– Any foot infection with the following signs of a systemic inflammatory response syndrome, as manifested by ≥2 of the following: • Temperature >38 or <36 °C • Heart rate >90 beats/min • Respiratory rate >20 breaths/min or PaCO ₂ <32 mmHg • White blood cell count >12 000 or <4000 cu/mm or 10% immature (band) forms	4 (severe infection)

¹In any direction.

be taken as evidence of infection. Some maintain that the presence of high numbers of bacteria (usually defined as $\geq 10^5$ colony forming units per gram per tissue) should be the basis for diagnosing infection [17], but no convincing data support this concept in the diabetic foot; furthermore, quantitative microbiology is rarely available outside of research laboratories. Thus, DFI must be diagnosed clinically (Table 1), with wound cultures reserved for determining the causative organisms and their antibiotic sensitivities. Clinical diagnosis rests on the presence of at least two local findings of inflammation, that is, redness (erythema or rubour), warmth (calour), pain or tenderness (dolour), induration (swelling or tumour) or purulent secretions [16]. Other (sometimes called secondary) features suggestive of infection include the presence of necrosis, friable or discoloured granulation tissue, non-purulent secretions, foetid odour or the failure of a properly treated wound to heal [18]. These may be helpful when local and systemic inflammatory signs are diminished because of peripheral neuropathy or ischemia [19–21]. Because infection can worsen quickly, the diagnosis should be pursued methodically [19] and aggressively [22]. All wounds must be carefully inspected, palpated and probed, both at initial presentation and on follow-up. Various imaging and laboratory studies may be useful in some cases to define the extent of soft tissue infection and any bone involvement.

Osteomyelitis

Accurately diagnosing bone infection can be difficult but is essential to ensure appropriate treatment. A definite diagnosis of osteomyelitis requires both the presence of histological findings consistent with bone infection (inflammatory cells, necrosis) and the isolation of bacteria from an aseptically obtained bone sample [2]. Because these procedures are not routinely available in many settings, clinicians must often use surrogate diagnostic markers, including clinical, laboratory and imaging findings.

The clinical presentation of osteomyelitis in the diabetic foot can vary with the site involved, the extent of infected and dead bone, the presence of associated abscess and soft tissue involvement, the causative organism(s) and the adequacy of limb perfusion. The main problems in diagnosing osteomyelitis are the delay in detecting bony changes in early infection on plain radiographs and the difficulty in distinguishing bony changes caused by infection from those related to Charcot neuro-osteoarthropathy (CN) on most imaging studies. As will be discussed, analyses from recent expert publications [2,23] and systematic reviews [2,24,25] provide guidance on the best diagnostic studies.

Clinical evaluation

Clinicians should suspect osteomyelitis when an ulcer overlying a bony prominence fails to heal despite adequate off-loading or when a toe is erythematous and indurated. The likelihood ratio (LR) of a clinician's suspicion of osteomyelitis is surprisingly good: positive LR 5.5 and

negative LR 0.54 [24,25]. The presence of exposed bone has a positive LR for osteomyelitis of 9.2; large ulcers (area $> 2 \text{ cm}^2$) are much more likely to have underlying bone infection than smaller ones [24–27]. Osteomyelitis can, however, occur in the absence of overlying local signs of inflammation [26].

Probe-to-bone test

This is a useful clinical diagnostic tool. Striking bone (detected by the hard, gritty feel) with a blunt sterile metal probe gently inserted through a wound increases the likelihood that the patient has osteomyelitis if the prevalence of bone infection is high (i.e. $> 60\%$) in the population under scrutiny [28,29]. Conversely, a negative probe-to-bone test in a patient at low risk (i.e. $\leq 20\%$) essentially rules out osteomyelitis [30–32].

Blood tests

The erythrocyte sedimentation rate is diagnostically useful; when elevated (usually defined as $> 70 \text{ mm/h}$), it increases the likelihood of osteomyelitis underlying a diabetic foot wound (positive LR 11), while lower levels reduce the likelihood (negative LR of 0.34) [24,26,33,34]. Based on fewer data, an elevated C-reactive protein, procalcitonin or blood leukocyte count may also be predictive of the presence of osteomyelitis [34,35].

Imaging studies

Plain radiography. Characteristic features of osteomyelitis on plain X-rays of the foot (usually two or three views) are summarized in Table 2 [26,36–38]. Among the many studies that have assessed the accuracy of plain radiography in diagnosing osteomyelitis [26,36,38–53], nine were prospective in design [26,36,38–41,44,45,52]. Overall, the

Table 2. Common imaging features of diabetic foot osteomyelitis

Plain radiographs
<ul style="list-style-type: none"> • Periosteal reaction or elevation • Loss of cortex with bony erosion • Focal loss of trabecular pattern or marrow radiolucency • New bone formation • Bone sclerosis with or without erosion • Sequestrum: devitalized bone with radiodense appearance that has become separated from normal bone • Involucrum: a layer of new bone growth outside existing bone resulting from the stripping off of the periosteum and new bone growing from the periosteum • Cloacae: opening in involucrum or cortex through which sequestra or granulation tissue may be discharged
Magnetic resonance imaging
<ul style="list-style-type: none"> • Low focal signal intensity on T1-weighted images • High focal signal on T2-weighted images • High bone marrow signal in short tau inversion recovery (STIR) sequences • Less specific or secondary changes: <ul style="list-style-type: none"> ○ Cortical disruption ○ Adjacent cutaneous ulcer ○ Soft tissue mass ○ Sinus tract formation ○ Adjacent soft tissue inflammation or oedema <p>For both modalities, bony changes are often accompanied by contiguous soft tissue swelling.</p>

sensitivity varied from 28% to 75%. The timing of the imaging greatly influences its usefulness, as longer-standing cases are more likely to show bony abnormalities on plain radiographs than those present for less than a couple of weeks. In the systematic review by Dinh *et al.* [25], the pooled sensitivity of the four eligible studies was 0.54 and the pooled specificity was 0.68, with a diagnostic odds ratio of 2.84 and a Q statistic of 0.60 [26,36,38,52]. In the systematic review by Butalia *et al.* [24], analysing seven studies of plain radiographs, the summary positive likelihood ratio was 2.3 [95% confidence intervals (CI) 1.6–3.3], while the negative likelihood ratio was 0.63 (95% CI 0.5–0.8) [26,36,38,43,47,48,50]. These results suggest that radiographic findings are only marginally predictive of osteomyelitis if positive and even less predictive of the absence of osteomyelitis if negative. Of note is that neither review identified a study that obtained sequential plain radiographs of the foot over time. Changes in radiological appearance over an interval of at least 2 weeks are more likely to predict the presence of osteomyelitis than a single study, although correctly targeted antibiotic therapy may prevent these changes.

Magnetic resonance imaging. Magnetic resonance imaging (MRI) is a valuable tool for diagnosing osteomyelitis, as well as defining the presence and anatomy of deep soft tissue infections [16]. The key features suggestive of osteomyelitis on MRI are listed in Table 2. In their meta-analysis, Dinh *et al.* [25] identified four trials using MRI, all of which were prospective [27,36,38,54] and two of which used a consecutive recruitment method [36,38], but only one was conducted within the past 10 years [27]. The prevalence of osteomyelitis in the four studies ranged from 44% to 86%. The pooled sensitivity of MRI for diabetic foot osteomyelitis (DFO) was 0.90 (CI 0.82–0.95), and the diagnostic odds ratio was 24.4. In 16 trials identified in the meta-analysis by Kapoor *et al.* [55], 9 were prospective studies and 11 included only subjects with diabetes, although enrolment criteria were quite varied. The prevalence of standard defined osteomyelitis was 50% (range 32% to 89%), the pooled sensitivity was 77–100% and the specificity was 40–100%. In subjects with diabetes, the diagnostic odds ratio was 42 (CI 15–120), the summary positive likelihood ratio was 3.8 (CI 0.2.5–5.8) and the summary negative likelihood ratio was 0.14 (CI 0.08–0.26) [27,36,38,41,45,49,51,56–64]. More recently performed studies reported lower diagnostic odds ratios (25, CI 6–117) compared with older ones, perhaps because their study designs were better. The subgroups of patients with other diagnoses (e.g. CN) were too small to analyse any differences among the studies.

Nuclear medicine. Three recent meta-analyses reviewed nuclear medicine techniques for evaluating the diabetic foot [25,55,65]. Capriotti *et al.* reviewed 57 papers, including seven reviews on the clinical value of several nuclear medicine methods [65]. Among the several types of nuclear imaging scans, a bone scan, usually performed with ^{99m}Tc -methylene diphosphate and done in time-sequence phases, is considered suggestive of osteomyelitis when it discloses increased blood-pool

activity and radionuclide intensity localized to the bone [25]. Three-phase bone scans are sensitive (90%), but not specific (46%) [65], with a calculated summary negative predictive value of 71% and positive predictive value of 65%. Among six studies with 185 subjects that qualified for the meta-analysis by Dinh *et al.* [25], the pooled sensitivity was 80%, but the specificity was only 28% [26,36,38,52,66,67]. The pooled diagnostic odds ratio was 2.1, indicating poor discriminating ability, while the Q statistic was 0.6, indicating moderate accuracy for the diagnosis of osteomyelitis [25]. On the basis of seven studies, Kapoor *et al.* [55] found the performance characteristics of a triple-phase bone scan were markedly inferior to MRI [38,41,45,49,58,63,64], with a diagnostic odds ratio of 3.5 (CI 1.0–13) versus 150 (CI 55–411), respectively [55]. Healthy bone may also have an increased uptake of the radiopharmaceutical, especially in the forefoot [65]. While a positive bone scan is certainly not specific for osteomyelitis (or CN), a negative one largely rules it out.

Radiolabelled white blood cells (usually using either ^{99m}Tc or ^{111}In) are generally not taken up by healthy bone, making positive leukocyte scans more specific than bone scans for diagnosing osteomyelitis (and excluding CN) [65]. In a review of these scans by Capriotti *et al.*, the summary positive predictive values for osteomyelitis were 90% and 72%, respectively, and the negative predictive values were 81% and 83%, respectively [65]. ^{99m}Tc labelling appears to provide superior physical characteristics, leading to better spatial resolution than ^{111}In [65]. In another recent review, Palestro and Love concluded that among radionuclide procedures, labelled leukocyte imaging is the best choice for evaluating diabetic pedal osteomyelitis, with a sensitivity of 72% to 100% and specificity of 67% to 98% [68]. Dinh *et al.* [25] identified six studies using ^{111}In -radiolabelled leukocytes, with a pooled sensitivity of 74% and a specificity of 68% [26,36,38,52,66,67]. The pooled diagnostic odds ratio was 10, indicating moderately good discriminating characteristics, while the Q statistic of 0.59 suggests a low to moderate accuracy for the diagnosis of osteomyelitis [25]. Kapoor *et al.* [55] found that in three studies, MRI outperformed leukocyte scanning (with ^{99m}Tc [64] or ^{111}In [45,49]) with diagnostic odds ratios of 120 (CI 62–234) and 3.4 (CI 0.2–62), respectively. The combination of labelled leukocytes with a bone scan (dual tracer technique) does not substantially improve diagnostic accuracy [46].

Other available nuclear medicine techniques include *in vivo* methods of labelling leukocytes, radiolabelled polyclonal IgG and radiolabelled antibiotics. Results of studies using these techniques have varied, and most of the methods are unavailable in many countries. ^{99m}Tc -/ ^{111}In labelled human immunoglobulin G uptake is related to vascular permeability, not inflamed tissue, and thus not as specific as radiolabelled leukocytes [50,69]. The pooled positive and negative predictive values for this technique, calculated from 97 lesions, were 72% and 88%, respectively [65].

Other imaging techniques. Two published studies of computer tomography (CT) and CT combined with positron

emission tomography (PET) scans for the diagnosis of osteomyelitis [25] did not include histopathological examination of bone [70,71]. A recent prospective study that enrolled 110 patients reported that PET/CT scan had a sensitivity of 81%, specificity of 93%, positive predictive value of 78%, negative predictive value 94% and accuracy of 90%, which was somewhat better than a simultaneous MRI [72]. While the data on this new procedure are limited, there seems to be a place for CT (especially if combined with PET) scans when MRI is unavailable or contraindicated.

Bone biopsy

The weight of current evidence supports evaluating a bone specimen as the best available diagnostic technique for both diagnosing bone infection and providing reliable data on the responsible organisms and their antibiotic susceptibility profile [3]. Soft tissue or sinus tract cultures are not sufficiently accurate in predicting bone pathogens [73,74]. Ideally, it would be best to process a bone specimen for both culture and histopathology. While infected bone usually has inflammatory cells (granulocytes early and mononuclear cells later), the histomorphology of uninfected bone is normal in diabetic patients, including in those with neuropathy or vasculopathy [75]. Unfortunately, both histology and culture may be misleading results. Culture of a bone specimen may be falsely negative because of sampling errors, prior antibiotic therapy or a failure to isolate fastidious organisms. It may also be falsely positive because of contamination by wound-colonizing flora not involved in bone infection. Similarly, bone histopathology may be falsely negative due to sampling error or potentially falsely positive due to some non-infectious inflammatory disorder. In a recent analysis of 44 patients, a comparison of microbiological and histopathological testing demonstrated that they performed similarly in identifying the presence of pedal osteomyelitis in the diabetic foot [76].

In one retrospective multicentre study, using bone culture-guided antibiotic treatment was associated with a significantly better clinical outcome than using soft tissue culture results [77]; this finding requires confirmation by a prospective study. While success rates of 75% or higher have been reported with empiric treatment of diabetic foot osteomyelitis (DFO) it is difficult to compare the results of available published studies because of their differences in the populations enrolled, in the criteria for both diagnosis and remission of infection and in durations of follow-up [78]. Bone culture is not always needed when DFO is suspected, but clinicians should consider this procedure when the diagnosis of osteomyelitis remains uncertain despite clinical and imaging evaluations, in cases of non-informative data from soft tissue cultures, when the infection has failed to respond to initial empiric antibiotic therapy or when considering an antibiotic regimen with a higher potential for selecting resistant organisms (e.g. rifampin, fluoroquinolones, fusidic acid or clindamycin) [2].

To reduce the likelihood of false-negative culture results, it is presumably best to perform bone biopsy after

an antibiotic-free period in clinically stable patients. As certain antibiotic agents have a prolonged release from bone tissue, holding antibiotics for 2 weeks is ideal, but even a couple of days may be helpful [79]. Because DFO (in the absence of substantial soft tissue infection) is typically a slowly progressive disease, such a delay is usually safe. Percutaneous biopsy of bone through clinically uninvolved skin reduces the likelihood of false positive culture, although one study found good results (based on favourable clinical outcome) using a simpler per-wound bone biopsy after careful debridement [79]. Similarly, while there are potential risks of bone biopsy, that is, tracking contaminating organisms into the bone or causing a bone fracture, several large series have shown that complications from percutaneous (and surgical) procedures are very rare [26,80]. Any properly trained physician (e.g. a foot surgeon, interventional radiologist) can perform the biopsy. Percutaneous biopsy should preferably be performed under fluoroscopic or CT guidance, traversing intact and uninfected skin. Patients with sensory neuropathy often do not need anaesthesia. If possible, the operator should attempt to obtain at least two specimens – one for culture and the other for histological analysis. With small toe bones, it may only be possible to aspirate a few bony spicules.

The presence of clinically significant foot ischemia makes both diagnosis and treatment of infection considerably more difficult.

Assessing severity

Accurately assessing a diabetic foot wound usually requires debridement of callus and necrotic tissue. Keys to classifying a foot infection are defining the extent of the tissues involved, determining the adequacy of arterial perfusion and assessing for systemic toxicity [16,82,83]. While mild infections are relatively easily treated, moderate infections may be limb threatening and severe infections may be life threatening (Table 3A). Infection severity largely guides the choice of antibiotic and its route of administration and helps to determine the need for hospitalisation (Table 3B), the potential necessity and timing of foot surgery and the likelihood of amputation [15,83–85].

Deep space infections may have deceptively few superficial signs, but clinicians should consider this possibility in a patient with systemic toxicity (e.g. fever, chills, leukocytosis), inflammation distant from the skin wound, persistent infection or elevated inflammatory markers despite appropriate therapy, or pain in a previously insensate foot [13,22,86].

Microbiological considerations

When to send specimens for culture

Knowing the likely etiologic agent(s) helps the clinician select appropriate antimicrobial therapy. Acute infections in previously untreated patients are usually caused by

Table 3. Characteristics suggesting a more serious diabetic foot infection and potential indications for hospitalization

(A) Findings suggesting a more serious diabetic foot infection	
Wound specific	
Wound	Penetrates into subcutaneous tissues, i.e., fascia, tendon, muscle, joint, bone
Cellulitis	Extensive (>2 cm), distant from ulceration or rapidly progressive
Local signs	Severe inflammation, crepitus, bullae, marked induration, discoloration, necrosis/gangrene, ecchymoses or petechiae
General	
Presentation	Acute onset or rapidly progressive
Systemic signs	Fever, chills, hypotension, confusion, volume depletion
Laboratory tests	Leukocytosis, severe or worsening hyperglycaemia, acidosis, azotaemia, electrolyte abnormalities
Complicating features	Presence of a foreign body (accidental or surgically implanted), puncture wound, abscess, arterial or venous insufficiency, lymphoedema
Current treatment	Progression while on apparently appropriate antibiotic therapy
(B) Factors suggesting hospitalization may be necessary	
• Severe infection (Table 3A)	
• Metabolic instability	
• Intravenous therapy needed (and not available/appropriate as outpatient)	
• Diagnostic tests needed that are not available as outpatient	
• Critical foot ischemia present	
• Surgical procedures (more than minor) required	
• Failure of outpatient management	
• Patient's inability or unwillingness to comply with outpatient-based treatment	
• Need for more complex dressing changes than patient/caregivers can provide	

aerobic gram-positive cocci (often as a monomicrobial infection) [87], but deep or chronic wounds may harbour polymicrobial flora, including gram-negative and anaerobic bacteria [82]. Skin disorders, environmental exposures or recent antibiotic therapy can predispose to unusual or antibiotic-resistant pathogens. Wound cultures are helpful for most infections but are difficult to obtain in cases with just cellulitis (where skin aspiration has limited sensitivity) and generally unnecessary for clinically uninfected lesions. Blood cultures are only needed for severe infections, and bone cultures help diagnose and direct therapy of osteomyelitis. In the past decade, molecular microbiological techniques have demonstrated a far more complex mix of organisms in DFIs [88,89], but the clinical significance of these isolates is not yet clear.

Obtaining specimens for wound cultures

A wound culture is useful only if the specimen is appropriately collected and processed. Antibiotic susceptibility results generally help in focusing (and often constraining) antibiotic regimens. Deep tissue specimens, obtained aseptically at surgery, usually contain only the true pathogens, while cultures of superficial lesions often yield contaminants [87,90]. Curettage (tissue scraping) with a curette or scalpel from the base of a debrided ulcer or needle aspirate of purulent secretions generally provides more accurate results than wound swabbing [87,91]. If swabs are the only available method, they should be taken only after debriding and cleaning the wound. Specimens should be sent to the laboratory promptly, in suitable sterile transport containers.

Interpreting wound culture results

Sole or predominant bacteria identified on culture (and, where available, Gram-stained smear) and isolated from

reliable specimens are likely true pathogens. If multiple organisms are isolated, especially from superficial ulcers, it can be difficult to determine which are pathogens. Targeting treatment against less virulent isolates (e.g. coagulase-negative staphylococci, corynebacteria) may be unnecessary. These species can, however, represent true pathogens, especially if they grow repeatedly or from reliable specimens. *Staphylococcus aureus* is the most frequently isolated and among the more virulent pathogens in DFIs; even when it is not the sole isolate, it is usually a component of a mixed infection. Streptococci (various groups of β -haemolytic and others) are also important pathogens. Enterococci are relatively frequent isolates but usually of secondary clinical importance.

Infections requiring hospitalisation are often polymicrobial, including aerobes and anaerobes [16,92]. Gram-negative bacilli (mainly Enterobacteriaceae, sometimes *Pseudomonas aeruginosa* or other non-fermentative species) are usually isolated in conjunction with gram-positive cocci from patients with chronic or previously treated infections; they are often, but not always, true pathogens. Many recent studies have reported that gram-negative organisms are the most frequent isolates in DFIs occurring in patients in warm climates, especially in developing countries [93–96]. It is unclear if this is related to environmental factors, footwear preferences, personal hygiene practices, antimicrobial pretreatment or other factors. Obligate anaerobic species are most frequent in wounds with ischaemic necrosis or those that involve deep tissues; they are rarely the sole pathogen and most often are part of a mixed infection with aerobes [97].

Multidrug-resistant organisms, especially methicillin-resistant *S. aureus* (MRSA), are more frequently isolated from patients who have recently received antibiotic therapy, have been previously hospitalized or reside in a chronic care facility [98]. After the rates of MRSA dramatically increased in many countries starting in the late

1990s, they have begun to decline in most recent reports, concomitant with improved hospital (and outpatient) infection control measures [99–101]. The previously useful distinction of community-acquired (less likely to be resistant to other antibiotics) *versus* healthcare-associated strains has become blurred in recent years. In some, but not all, reports on DFIs, those caused by MRSA have been associated with worse outcomes, that is, higher clinical failure and amputation rates [102–104]. In the past decade, other multidrug-resistant organisms, especially gram-negatives with extended-spectrum beta-lactamases (ESBL) and occasionally vancomycin-resistant enterococci, have been more commonly isolated from DFIs [96,105,106]. ESBL-producing organisms usually require treatment with very broad-spectrum antibiotics, that is, carbapenems. Fungi may be isolated from both infected and uninfected foot wounds, but this rarely necessitates systemic antifungal therapy [107]. They are, however, a frequent cause of onychomycosis.

Bone infection

DFO can present the clinician with formidable diagnostic and therapeutic challenges [78]. It complicates about 50% to 60% of serious, and 10% to 20% of apparently less severe, foot infections in patients presenting to diabetic foot clinics. Bone infection typically occurs by contiguous spread from overlying soft tissue, which may penetrate through the cortex into the marrow. Bone destruction caused by neuroarthropathy (CN) may be difficult to distinguish from that caused by infection, although the former is less common, tends to occur in patients with profound peripheral neuropathy but adequate arterial perfusion, more frequently involves the midfoot and often occurs in the absence of a skin break [108,109]. Many cases of osteomyelitis are monomicrobial, but most are polymicrobial; *S. aureus* is the most commonly isolated agent (~50% of cases), while *S. epidermidis* (~25%), streptococci (~30%) and Enterobacteriaceae (~40%) are also frequent isolates [108].

Treatment

Patients with a severe infection (Table 3A) should usually be hospitalised, as they often require surgical interventions, fluid resuscitation and control of metabolic derangements. Also, consider admitting patients with moderate infections if they are unable or unwilling to be adequately involved in wound care, can or will not be able to off-load the affected area, are unlikely to comply with antibiotic therapy, require parenteral antibiotic therapy (that is not available as an outpatient) or need close monitoring of treatment response (Table 3B). Most other patients with a moderate infection, and almost all with a mild infection, can cautiously be treated as outpatients, with instructions to return if the infection worsens or in-office re-evaluation every few days initially [91].

Surgery is the cornerstone of treating many deep soft tissue infections [86], and early intervention might be associated with better outcomes [22,110–112]. Intervening emergently, however, is only needed in specific circumstances, such as severe infection in an ischaemic limb; an abscess accompanied by compartment syndrome or necrosis; systemic sepsis syndrome; or local infection with bullae, ecchymoses, extreme pain or unexpected anaesthesia. The treating clinician should consider the need for surgery in every infection, which may range from minor debridement or drainage to extensive resections or major amputation. When the wound has a dry eschar, especially in an ischemic foot, it is often best to avoid debriding the necrotic tissue. Major amputation should, and usually can, be avoided except when the limb is non-viable, is affected by life-threatening infection (e.g. gas gangrene or necrotizing fasciitis) or is functionally useless. Revascularisation may be needed for an infected ischemic limb. Surgeons operating on a patient with a DFI should have adequate knowledge of the complex anatomy of the foot [22,113]. Figure 1 shows an algorithmic overview of the approach to treating a diabetic patient with a foot lesion.

Antimicrobial therapy

Indications for therapy

Infected diabetic foot wounds require antibiotic therapy, as failure to properly treat infected wounds is usually associated with progressive tissue destruction and poor wound healing. Because antibiotic therapy is associated with frequent adverse effects, financial costs and increasing risk of antibiotic resistance [98], it should be reserved for treating wounds that are infected. Using antimicrobial therapy has not been proven beneficial for managing clinically uninfected skin wounds, irrespective of theoretical considerations of the bacterial 'bioburden' of chronic wounds [114–118]. There is no published evidence that they either accelerate wound healing or reduce the likelihood of clinical infection developing. Where the clinical assessment for the presence of infection is equivocal, the clinician must make a decision to treat the wound either as uninfected or as infected (using an infection grading system) and then carefully monitor progress.

Route of therapy

For an antibiotic to reach a therapeutic concentration at the site of infection, it must first achieve an adequate serum level [119]. Because parenteral antibiotics achieve faster and higher serum levels, they are recommended for patients who are systemically ill or have a severe infection. They may also be required for those unable to tolerate oral agents or who are infected with pathogens insensitive to oral agents. After the patient's clinical condition has stabilized and the infection is responding, most can switch to oral therapy. Where available, outpatient intravenous therapy can be used for those requiring prolonged parenteral treatment, for example for some cases of osteomyelitis or infections resistant to oral agents.




Figure 1. Approach to the infected diabetic foot

Compared with parenteral therapy, oral antibiotics are more convenient, generally associated with fewer complications and are less expensive. Gastrointestinal absorption of oral antibiotics, while variable, is excellent for several agents. Fluoroquinolones in particular achieve high tissue concentrations in DFIs [119–121], even in patients with gastroparesis [122], but most other currently used oral antibiotics also achieve adequate serum and tissue levels. Newly marketed agents generally have an expanded spectrum of activity, greater activity against antibiotic-resistant gram-positive cocci, a longer half-life (allowing for less frequent dosing) and good oral bioavailability. They are, however, generally considerably more expensive and have a shorter track record for safety evaluations.

Peripheral vascular disease, but not diabetes alone, may limit the delivery, and therefore penetration, of antibiotics to infected foot tissues [122,123]. Even in an ischemic limb, however, antibiotics play an important role in preventing further spread of infection. Problems with limb arterial insufficiency have led some to experiment with novel methods of antibiotic delivery to the lower limb, for example retrograde intravenous perfusion under pressure [124,125], intra-arterial (e.g. femoral) administration [126] or primary closure of debrided wounds with catheter instillation of antibiotics [127]. These techniques have not yet proven their usefulness.

Using topical antibiotic therapy for a foot wound is appealing, as it allows high concentrations at the site of infection without potentially toxic systemic levels [128]. It also allows treatment with agents not available for systemic therapy. While not appropriate when there is extensive (>2 cm) cellulitis, a large randomized trial found an investigational topical antibiotic peptide (pexiganan) as effective as oral therapy with a fluoroquinolone for mildly infected diabetic foot ulcers [129]. A limited number of marketed topical antimicrobial agents, as well as antimicrobial impregnated wound dressings (e.g. those containing various forms of silver and iodine), might be useful for preventing, or possibly treating, mild infections [115]. Available data are too limited to recommend local antimicrobial treatment, but further research is warranted [130–132]. For deep wounds, antibiotic-loaded beads, cement or biodegradable bovine collagen sponges can supply high local antibiotic concentrations for a long duration and, in some instances, fill dead space [133,134]. A recent systematic review concluded that the data supporting the use of gentamicin-loaded beads is too limited to allow making recommendations [135].

Choice of antibiotics

Initial antibiotic regimens are usually empirical. These should cover the most common pathogens but be modified according to infection severity and available clinical

or microbiological clues. Relatively narrow-spectrum agents are preferred for minor infections, with adjustments if clinical response is inadequate. Initial regimens for severe infections should be a broader spectrum, and treatment must be delivered promptly. An empirical regimen must also take into consideration factors related to the current infection, the likely pathogen(s), the specific patient and potential drug-related issues (Table 4). A Gram-stained smear of a wound specimen may help direct empiric antibiotic therapy by informing the clinician of the number and gram types of pathogens present [136].

An empiric regimen should virtually always include an antibiotic active against non-resistant isolates of staphylococci and streptococci. Consider adding an agent active against MRSA if the patient has risk factors for this organism (e.g. recent stay in healthcare setting, recent antibiotic therapy or known MRSA colonization). Patients who have been previously treated with an antibiotic (for whatever reason), or who have a more severe infection, may need extended coverage for common gram-negative bacilli and perhaps for *Enterococcus* species. Empiric anti-anaerobic therapy is appropriate for necrotic, gangrenous or foul-smelling wounds. Combination therapy may be appropriate for infections presumed (or proven) to be caused by more than one organism, when the pathogen has a high potential for developing resistance (e.g. *Pseudomonas*) or when selecting an agent (e.g. rifampin) to which resistance may quickly develop when used alone.

When culture and sensitivity results are available, consider changing to a more specific regimen targeted at the isolated pathogens. To reduce the likelihood of antibiotic resistance, narrower spectrum agents are preferable, but it is important to assess how the infection has responded

Table 4. Factors that may influence choices of antibiotic therapy for diabetic foot infections (specific agents, route of administration and duration of therapy)

Infection related
– Clinical severity of the infection (Table 1)
– History of antibiotic therapy within previous 3 months
– Presence of bone infection (presumed or proven)
Pathogen related
– Likelihood of non-GPC etiologic agent(s)
– History of colonisation or infection with MDROs
– Local rates of antibiotic resistance
Patient related
– Allergies to antibiotics
– Impaired immunological status
– Patient treatment preferences
– Renal or hepatic insufficiency
– Impaired gastrointestinal absorption
– Arterial insufficiency in affected limb
– Exposure to environment with high risk of MDROs or unusual pathogens
Drug related
– Safety profile (frequency and severity of adverse effects)
– Drug interactions potential
– Frequency of dosing
– Formulary availability/restrictions
– Cost considerations (acquisition and administration)
– Approval for indication
– Likelihood of inducing <i>C. difficile</i> disease or antibiotic resistance
– Published efficacy data

GPC, gram-positive cocci (aerobic); MDRO, multidrug-resistant organism.

to the empirical regimen. If the infection is improving and the patient is tolerating therapy, there may be no reason to change, even if some or all of the isolated organisms are resistant to the agents prescribed [137]. If the infection is not responding, however, modify treatment to cover all isolated organisms. If the infection is worsening despite the isolated bacteria being susceptible to the selected regimen, reconsider whether surgical intervention is needed, the possibility that fastidious infecting organisms were not recovered on culture or that patient adherence to the treatment regimen has been suboptimal.

Several antibiotic agents have been used successfully to treat DFIs for decades, despite not having been evaluated in prospective comparative studies; these include penicillinase-resistant penicillins (e.g. dicloxacillin, nafcillin), cephalosporins (e.g. cefazolin, ceftriaxone), glycopeptides (teicoplanin), rifampin, fusidic acid, pristinamycin, trimethoprim-sulfamethoxazole and doxycycline. Agents that have demonstrated clinical effectiveness, alone or in combination, in published prospective studies of DFIs include the following (Table 5) [3]:

- Cephalosporins (cephalexin orally; cefoxitin and ceftizoxime, parenterally)
- Penicillin/ β -lactamase inhibitor congeners (amoxicillin/clavulanate, orally; ampicillin/sulbactam, piperacillin/tazobactam and ticarcillin/clavulanate, parenterally)
- Carbapenems (imipenem/cilastatin and ertapenem, parenterally)
- Fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin and moxifloxacin, all both orally and parenterally)
- Other agents: clindamycin (orally and parenterally); amdinocillin (parenterally); linezolid (orally and parenterally); daptomycin (parenterally); and vancomycin (parenterally)

Other agents in the same antibiotic classes as those listed (or in Table 5) are also likely to be effective. Overall, the clinical and microbiological response rates have been similar in published trials with various antibiotics, and there is no one preferred agent or combination [2,3,103,138,139]. Understanding the principles of antibiotic therapy is more important than knowing the specific agents currently in favour, especially as new antibiotics are introduced and some older ones are made obsolete by emergence of resistance or newly appreciated toxicities [136,138]. In the absence of a compelling reason to choose a specific antibiotic, the one with the lowest acquisition cost is preferred, even though antibiotics account for only a small portion of the treatment costs for a foot infection [140]. There is a compelling need for comparative trials and economic analyses of various anti-infective regimens for DFIs [141,142]. Suggested empirical antibiotic regimens, by type of infection, are given in Table 5.

Duration of therapy

The optimal duration of antibiotic therapy for various types of DFIs is unknown. On the basis of data from available studies, for mild to moderate infections, 1 to 2 weeks

Table 5. Selecting an empiric antibiotic regimen for diabetic foot infections

Infection severity	Additional factors	Usual pathogen(s)	Potential empirical regimens ¹
Mild	No complicating features	GPC (staphylococci or streptococci)	S-S pen; first gen Ceph ²
	Recent antibiotic exposure Beta-lactam allergy or intolerance	GPC + GNR	β -L-ase-1; T/S; FQ Clindamycin; FQ; T/S; macrolide
	High risk for MRSA	MRSA	Linezolid; T/S; doxycycline
Moderate and severe ³	No complicating features Recent antibiotics	GPC \pm GNR	β -L-ase 1; second/third gen Ceph β -L-ase 2; second/third gen Ceph, group 1 carbapenem (depends on prior therapy; seek advice) FQ; β -L-ase 2; group 2 carbapenem
	Macerated ulcer, warm climate	GNR, including <i>Pseudomonas</i>	FQ; β -L-ase 2; group 2 carbapenem
	Ischemic limb/necrosis/gas forming	GPC \pm GNR \pm anaerobes	β -L-ase 1 or 2; group 1 or 2 carbapenem; or second/third gen Ceph + clindamycin or metronidazole
	MRSA risk factors	MRSA	Consider addition of, or substituting with, glycopeptides, linezolid, daptomycin; fusidic acid, T/S, doxycycline
	Risk factors for resistant GNR	<i>Pseudomonas</i> */ESBL	Pip/tazo*, carbapenems, FQ, aminoglycoside, colistin

β -L-ase = β -lactam, β -lactamase inhibitor.

β -L-ase 1 = amoxicillin/clavulanate, ampicillin/sulbactam.

β -L-ase 2 = ticarcillin/clavulanate, piperacillin/tazobactam.

Group 1 carbapenem = ertapenem.

Group 2 carbapenem = imipenem, meropenem, doripenem.

Ceph = cephalosporin; gen = generation.

Pip/tazo = piperacillin/tazobactam.

FQ = fluoroquinolone with good activity against aerobic gram-positive cocci (e.g. levofloxacin or moxifloxacin).

T/S = trimethoprim/sulfamethoxazole.

ESBL, extended-spectrum beta-lactamase; GPC, gram-positive cocci (aerobic); GNR, gram-negative rods; MRSA, methicillin-resistant *Staphylococcus aureus*.

¹Given at usual recommended doses for serious infections. Modify doses or agents selected for azotaemia, liver dysfunction etc. Recommendations based upon theoretical considerations and available clinical trials.

²A high local prevalence of methicillin resistance among staphylococci may require using vancomycin or other appropriate anti-staphylococcal agents active against these organisms.

³Oral antibiotic agents should generally not be used for severe infections, except as follow-on (switch) after initial parenteral therapy.

is usually effective [3,91], while for more serious infections, 2 to 4 weeks is usually sufficient [3,137,143–145]. Antibiotic therapy can generally be discontinued when signs and symptoms of infection have resolved, even if the wound has not healed – antibiotics are employed to cure infection, not heal wounds. More extended treatment may be needed for immunocompromised patients, for wounds that are poorly perfused, deep, large or necrotic or for osteomyelitis (*vide infra*), but this decision should be accompanied by clinical re-evaluations to justify and document the treatment strategy. The necessary duration of therapy may be shortened by adequate debridement, resection or amputation of infected tissue. Some patients who cannot (or refuse to) undergo surgical resection, or who have an implanted foreign body at the infection site, may require prolonged or intermittent suppressive antibiotic therapy.

Wound care

For DFIs, antibiotics are necessary but not sufficient to overcome inadequate vascular supply, poor glycaemic control or improper wound care [146,147]. Most wounds need to be carefully cleaned and debrided of necrotic tissue and surrounding callus. Those with heavy exudate

need a dressing that absorbs the moisture, while dry wounds heal best in a moist environment. Dressings should optimally be changed at least daily, to allow careful examination of the wound. Published studies do not adequately support using any available topical antimicrobials on most wounds. For patients with a DFI, it is best not to use a device (e.g. a total contact cast, topical negative pressure) that does not allow easy daily visualization of the wound. Remove or redistribute any pressure from the wound by encouraging the patient to be non-ambulatory or by providing an appropriate off-loading device.

Treating osteomyelitis

The IWGDF has produced a full systematic review of, and guidelines for, the treatment of DFO [2]. Among the important factors to consider when treating osteomyelitis are the following: the anatomic site of infection, the local vascular supply, the extent of soft tissue and bone destruction, the presence of systemic signs of infection and the patient's preferences. While many cases of DFO require, or benefit from, surgical debridement or resection of bone, some can be treated successfully by medical therapy alone. Several published retrospective series have shown

that DFO can be arrested (or even apparently cured) with antibiotic therapy and no surgical intervention in about two-thirds of cases [77,148–150]. In these reports, clinicians have generally employed antibiotic doses at the higher recommended ranges and given for at least two (and usually 3–6) months. Unfortunately, available studies do not provide information to inform which cases may require surgery [77,148–150]. In some cases, limited surgery combined with antibiotic therapy may be most appropriate [112].

The choice of an antimicrobial agent for osteomyelitis should optimally be based on the results of a bone culture, especially because of the need for long-duration therapy [77,108]. If empiric therapy is necessary, always select a regimen that covers *S. aureus*, as it is the most common pathogen; the patient's history or culture results may suggest a need for broader coverage. Some antibiotics may not penetrate well to infected bone, but the unreliability of measuring bone levels limits the value of published data on this issue. Furthermore, the association between high bone levels of antibiotics and improved outcome has not yet been studied. Traditionally, treatment of osteomyelitis has usually been parenteral (at least initially) and prolonged (at least 4 weeks), but these recommendations are not based on strong data. Many patients can probably be switched to oral therapy after about a week of parenteral treatment. Any oral antibiotics selected should have good bioavailability [e.g. fluoroquinolones, rifampin (always combined with another agent), clindamycin or trimethoprim–sulfamethoxazole]. If all of the infected bone is surgically removed, a shorter course of antibiotic therapy (i.e. 2–14 days) may be sufficient, depending on the status of the soft tissues [3]. Extending post-debridement antibiotic therapy beyond six weeks, or giving IV treatment longer than one week, does not appear to increase the remission rate [151]. For some patients with apparently incurable infection, long-term suppressive therapy, or intermittent short courses of treatment for recrudescing symptoms, may be the most appropriate approach. Antibiotic impregnated beads [133] or orthopaedic implants have been used successfully to treat DFO in a few small series [134].

Adjunctive therapies

Several studies have reported the results of additional measures used in an effort to improve infection resolution, wound healing or host response. These include negative pressure wound therapy, recombinant granulocyte colony stimulating factor (G-CSF), systemic hyperbaric oxygen (HBO) and larval (maggot) therapy. The available evidence does not support that any of these should be routinely used specifically for treatment of infection. There may, however, be a role for some or all in the overall care of the patient with a diabetic foot wound, though the evidence for cost effectiveness remains weak. On the basis of the results of a meta-analysis of generally low-quality studies, G-CSF therapy is associated with significantly

fewer surgical procedures, including amputations and duration of hospital stay, but not with the likelihood of resolution of infection, wound healing or the duration of systemic antibiotic therapy [3,152]. For HBO therapy, systematic reviews of largely poor quality randomised controlled trials (RCTs) [153], and a more recent well-done RCT [154], suggest a potential role in wound healing but have provided no evidence for a role in treating soft tissue or bone infection. For treating onychomycosis, there are many suggested remedies, including topical and oral medications and device-related methods. While oral antifungal therapy (e.g. itraconazole, terbinafine) is perhaps the best current treatment, newer methods (e.g. improved nail penetrating topical compounds, light based devices) appear to be promising [155].

Outcome of treatment

With appropriate treatment, the signs and symptoms of mild infections almost always resolve without need for amputation. When infection involves deep soft tissue structures or bone, the outcome is often less favourable; many require surgical debridement, bone resection or partial amputations. With extensive infection, or in medical centres with limited expertise or resources, lower extremity amputation rates may reach 50–60% [3,156]. In the hands of an experienced surgeon, most amputations can be foot sparing (i.e. below the malleoli), and long-term control of infection is achieved in over 80% of cases [157]. The presence of limb or foot ischemia has an important adverse effect on the outcome, synergising with infection to worsen the prognosis [158].

Unfortunately, having had one foot infection is associated with an increased likelihood of another; foot infection recurs in 20% to 30% of diabetic patients, especially those with underlying osteomyelitis [159]. While it is difficult to know when osteomyelitis is cured, evidence suggesting remission includes a drop in the erythrocyte sedimentation rate or C-reactive protein level, reconstitution of destroyed bone on plain radiograph and healing of any overlying soft tissue wound. Factors that predict healing include the absence of any exposed bone, palpable pedal pulses, blood pressure in the toe of >45 mmHg or in the ankle of >80 mmHg, a peripheral white blood cell count of <12 000/mm³ and a lower extremity transcutaneous oxygen tension of >40 mmHg [9,160]. Because of the risk of reinfection, educating patients who have a DFI on prevention techniques and encouraging prompt consultation for foot problems are critical. While much has been learned about diagnosing and treating infections in the past few decades, many fundamental questions remain, and more research is required.

Issues of particular importance in developing countries

These guidelines must, of course, be adapted to the local circumstances in which a healthcare provider sees

patients. Many aspects of the management of DFIs may differ in developing, compared with more developed, countries. To begin with, in developing countries, infections are often a consequence of wounds caused by the diabetic person either wearing footwear that is not sufficiently protective (e.g. sandals) or poorly fitting, or wearing none at all. Moreover, the person may delay seeing a healthcare provider for a longer period of time because of a lack of financial resources, nearby clinics or proper education. During this period, the patient may attempt to treat the infection with various home remedies, including plants or other locally accepted treatments. Patients can often buy antibiotics without a prescription in developing countries; thus, they will often have treated themselves, sometimes with the advice of a pharmacist or other trusted but non-licensed persons, before presenting to a physician. This unsupervised treatment, sometimes with expired medications at inadequate doses, is likely to result in infections caused by more antibiotic-resistant organisms.

Healthcare providers in developing countries may also face added difficulties. They may not have access to a microbiology laboratory, so they cannot ascertain the identity and antibiotic susceptibility of foot pathogens infecting an individual patient or of current isolates in the community. Similarly, many will not have access to even basic (not to mention more sophisticated) imaging equipment. Even when a patient sees a physician and receives an antibiotic prescription, indigent patients may be unable to purchase the full course of therapy or may be prescribed inexpensive but potentially more toxic or less effective agents. Home or work circumstances may make it very difficult for them to stay off their foot, or to afford or be able to use an off-loading device. Furthermore, they may have travelled a long distance to see a physician and cannot easily return for follow-up visits. Improving management of DFIs in developing countries will likely require a combination of education (for patients,

pharmacists and healthcare providers) and funding (for diagnostic, therapeutic and preventative services).

Acknowledgements

We thank the following, who served as corresponding members of the Expert Panel:

Dr Z. G. Abbass, Tanzania
 Dr F. J. Aragón Sánchez, Spain
 Dr M. Eneroth, Sweden
 Dr B. M. Ertugrul, Turkey
 Dr H. Gawish, Egypt
 Dr I. Gurieva, Russia
 Dr A. Jirkovska, Czech Republic
 Dr F. de Lalla, Italy
 Dr S. Kono, Japan
 Dr A. Nather, Singapore
 Dr J.-L. Richard, France
 Dr N. Rojas, Chile
 Dr L. Tudhope, South Africa
 Dr S. Twigg, Australia
 Dr V. Viswanathan, India
 Dr O. Udovichenko, Russia
 Dr D. Yue, Australia
 Dr Z. Xu, China

We thank Dr Karel Bakker for his support, guidance, insights and leadership.

Conflict of interest

BAL has served as a consultant to Merck, Pfizer, Cubist, DiPexium, Johnson & Johnson. ARB was a Pfizer Visiting Professor in 2011 to the University of Washington Department of Allergy and Infectious Diseases, an educationally unrestricted programme for which funding was awarded to DAID on a peer reviewed and competitive basis. ARB received no personal financial benefit from this programme. ES has served as an investigator in the EU-CORE database study (NOVARTIS).

References

- Lipsky BA, Berendt AR, Embil J, de Lalla F. Diagnosing and treating diabetic foot infections. *Diabetes Metab Res Rev* 2004; **20**(Suppl 1): S56–S64.
- Berendt AR, Peters EJ, Bakker K, *et al.* Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. *Diabetes Metab Res Rev* 2008; **24**(Suppl 1): S145–S161.
- Peters EJ, Lavery LA, Urbancic V, *et al.* A systematic review of the effectiveness of interventions in the management of infection in the diabetic foot. *Diabetes Metab Res Rev* 2012; **28**(Suppl. 1): X-XX.
- International Working Group on the Diabetic Foot. International Consensus on the Diabetic Foot and Supplements, DVD. International Diabetes Federation: Amsterdam, the Netherlands, 2007.
- Pecoraro RE. Chronology and determinants of tissue repair in diabetic lower extremity ulcers. *Diabetes*. 1991; **40**: 1305–1313.
- Pecoraro RG. Risk factors for amputation in patients with diabetes mellitus: a case control study. *Ann Intern Med*. 1992; **117**(2): 97–105.
- Lipsky BA. Infectious problems of the foot in diabetic patients. In: *The Diabetic Foot* (6th ed edn), Bowker JH, Pfeifer MA (eds). : Mosby, St. Louis, 2001; 467–480.
- Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. *Diabetes Care*. 2006; **29**(6): 1288–1293.
- Prompers L, Schaper N, Apelqvist J, *et al.* Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIABE Study. *Diabetologia*. 2008; **51**(5): 747–755.
- Wilson RM. Neutrophil function in diabetes. *Diabet Med*. 1986; **6**: 509–12.
- Bistrian MM. Host defenses and susceptibility to infection in patients with diabetes mellitus. *Infect Dis Clin North Am*. 1995; **9**(1): 1–9.
- Sentochnik DE, Eliopoulos GM. Infection and diabetes. In: *Joslin's Diabetes Mellitus* (13th ed edn), Kahn CR, Weir GC (eds). Lea & Febiger: Philadelphia, 1994; 867–868.
- Bridges RM, Jr., Deitch EA. Diabetic foot infections. Pathophysiology and treatment. *Surg Clin North Am*. 1994; **74**(3): 537–555.
- Lavery LA, Peters EJ, Williams JR, Murdoch DP, Hudson A, Lavery DC. Re-evaluating the way we classify the diabetic

- foot: restructuring the diabetic foot risk classification system of the International Working Group on the Diabetic Foot. *Diabetes Care*. 2008; **31**(1): 154–6.
15. Lavery LA, Armstrong DG, Murdoch DP, Peters EJ, Lipsky BA. Validation of the Infectious Diseases Society of America's diabetic foot infection classification system. *Clin Infect Dis*. 2007; **44**(4): 562–5.
 16. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. *Clin Infect Dis*. 2004; **39**(7): 885–910.
 17. Gardner SE, Hillis SL, Frantz RA. Clinical signs of infection in diabetic foot ulcers with high microbial load. *Biol Res Nurs*. 2009; **11**(2): 119–128.
 18. Cutting KF, White R. Defined and re-defined: criteria for identifying wound infection revisited. *Br J Community Nurs*. 2004; **9**(3): S6–S15.
 19. Edelson GW, Armstrong DG, Lavery LA, Caicco G. The acutely infected diabetic foot is not adequately evaluated in an inpatient setting. *Arch Intern Med*. 1996; **156**(20): 2373–6.
 20. Eneroth M, Apelqvist J, Stenstrom A. Clinical characteristics and outcome in 223 diabetic patients with deep foot infections. *Foot Ankle Int*. 1997; **18**(11): 716–722.
 21. Armstrong DG, Perales TA, Murff RT, Edelson GW, Welchon JG. Value of white blood cell count with differential in the acute diabetic foot infection. *J Am Podiatr Med Assoc*. 1996; **86**(5): 224–7.
 22. Aragón-Sánchez J. Seminar review: a review of the basis of surgical treatment of diabetic foot infections. *Int J Low Extrem Wounds*. 2011; **10**(1): 33–65.
 23. Teh J, Berendt T, Lipsky BA. Rational imaging. Investigating suspected bone infection in the diabetic foot. *BMJ*. 2009; **339**: b4690.
 24. Butalia S, Palda VA, Sargeant RJ, Detsky AS, Mourad O. Does this patient with diabetes have osteomyelitis of the lower extremity? *JAMA* 2008; **299**(7): 806–813.
 25. Dinh MT, Abad CL, Safdar N. Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: meta-analysis. *Clin Infect Dis*. 2008; **47**(4): 519–527.
 26. Newman LG, Waller J, Palestro CJ, et al. Unsuspected osteomyelitis in diabetic foot ulcers. Diagnosis and monitoring by leukocyte scanning with indium in 111 oxyquinoline. *JAMA* 1991; **266**(9): 1246–51.
 27. Ertugrul MB, Baktiroglu S, Salman S, Unal S, Aksoy M, Berberoglu K, Calangu S. The diagnosis of osteomyelitis of the foot in diabetes: microbiological examination vs. magnetic resonance imaging and labelled leucocyte scanning. *Diabet Med*. 2006; **23**(6): 649–653.
 28. Aragón-Sánchez J, Lipsky BA, Lázaro-Martínez JL. Diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients? *Diabet Med*. 2011; **28**(2): 191–194.
 29. Morales LR, González Fernández ML, Martínez HD, Beneit Montesinos JV, Guisado Jiménez S, Gonzalez Jurado MA. Validating the probe-to-bone and other tests for diagnosing chronic osteomyelitis in the diabetic foot. *Diabetes Care* 2010; **33**(10): 2140–2145.
 30. Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. *JAMA* 1995; **273**(9): 721–723.
 31. Shone A, Burnside J, Chipchase S, Game F, Jeffcoate W. Probing the validity of the probe-to-bone test in the diagnosis of osteomyelitis of the foot in diabetes. *Diabetes Care*. 2006; **29**(4): 945.
 32. Lavery LA, Armstrong DG, Peters EJ, Lipsky BA. Probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic? *Diabetes Care*. 2007; **30**(2): 270–4.
 33. Kaleta JL, Fleischli JW, Reilly CH. The diagnosis of osteomyelitis in diabetes using erythrocyte sedimentation rate: a pilot study. *J Am Podiatr Med Assoc*. 2001; **91**(9): 445–450.
 34. Armstrong DG, Lavery LA, Sariaya M, Ashry H. Leukocytosis is a poor indicator of acute osteomyelitis of the foot in diabetes mellitus. *J Foot Ankle Surg*. 1996; **35**(4): 280–283.
 35. Dinh T, Snyder G, Veves A. *Current techniques to detect foot infection in the diabetic patient* *Int J Low Extrem Wounds*. 2010; **9**(1): 24–30.
 36. Weinstein D, Wang A, Chambers R, Stewart CA, Motz HA. Evaluation of magnetic resonance imaging in the diagnosis of osteomyelitis in diabetic foot infections. *Foot Ankle*. 1993; **14**(1): 18–22.
 37. Mettler MA. *Essentials of Radiology*. Philadelphia, PA: Elsevier Saunders, 2005.
 38. Yuh WT, Corson JD, Baraniewski HM, et al. Osteomyelitis of the foot in diabetic patients: evaluation with plain film, 99mTc-MDP bone scintigraphy, and MR imaging. *AJR Am J Roentgenol*. 1989; **152**(4): 795–800.
 39. Wang A, Weinstein D, Greenfield L, et al. MRI and diabetic foot infections. *Magn Reson Imaging*. 1990; **8**(6): 805–809.
 40. Johnson JE, Kennedy EJ, Shereff MJ, Patel NC, Collier BD. Prospective study of bone, indium-111-labeled white blood cell, and gallium-67 scanning for the evaluation of osteomyelitis in the diabetic foot. *Foot Ankle Int*. 1996; **17**(1): 10–16.
 41. Enderle MD, Coerper S, Schweizer HP, et al. Correlation of imaging techniques to histopathology in patients with diabetic foot syndrome and clinical suspicion of chronic osteomyelitis. *The role of high-resolution ultrasound*. *Diabetes Care*. 1999; **22**(2): 294–299.
 42. Lee SM, Lee RG, Wilinsky J, Balogh K, Clouse ME. Magnification radiography in osteomyelitis. *Skeletal Radiol*. 1986; **15**(8): 625–627.
 43. Park HM, Wheat LJ, Siddiqui AR, et al. Scintigraphic evaluation of diabetic osteomyelitis: concise communication. *J Nucl Med*. 1982; **23**(7): 569–573.
 44. Shults DW, Hunter GC, McIntyre KE, Parent FN, Piotrowski JJ, Bernhard VM. Value of radiographs and bone scans in determining the need for therapy in diabetic patients with foot ulcers. *Am J Surg*. 1989; **158**(6): 525–529.
 45. Croll SD, Nicholas GG, Osborne MA, Wasser TE, Jones S. Role of magnetic resonance imaging in the diagnosis of osteomyelitis in diabetic foot infections. *J Vasc Surg*. 1996; **24**(2): 266–270.
 46. Keenan AM, Tindel NL, Alavi A. Diagnosis of pedal osteomyelitis in diabetic patients using current scintigraphic techniques. *Arch Intern Med*. 1989; **149**(10): 2262–2266.
 47. Larcos G, Brown ML, Sutton RT. Diagnosis of osteomyelitis of the foot in diabetic patients: value of 111In-leukocyte scintigraphy. *AJR Am J Roentgenol*. 1991; **157**(3): 527–531.
 48. Seldin DW, Heiken JP, Feldman F, Alderson PO. Effect of soft-tissue urethral pathology on detection of pedal osteomyelitis in diabetics. *J Nucl Med*. 1985; **26**(9): 988–993.
 49. Levine SE, Neagle CE, Esterhai JL, Wright DG, Dalinka MK. Magnetic resonance imaging for the diagnosis of osteomyelitis in the diabetic patient with a foot ulcer. *Foot Ankle Int*. 1994; **15**(3): 151–156.
 50. Oyen WJ, Netten PM, Lemmens JA, et al. Evaluation of infectious diabetic foot complications with indium-111-labeled human nonspecific immunoglobulin G. *J Nucl Med*. 1992; **33**(7): 1330–1336.
 51. Vesco L, Boulahdour H, Hamissa S, et al. The value of combined radionuclide and magnetic resonance imaging in the diagnosis and conservative management of minimal or localized osteomyelitis of the foot in diabetic patients. *Metab Clin Exp*. 1999; **48**(7): 922–927.
 52. Harwood SJ, Valdivia S, Hung GL, Quenzer RW. Use of Sulesomab, a radiolabeled antibody fragment, to detect osteomyelitis in diabetic patients with foot ulcers by leukoscintigraphy. *Clin Infect Dis*. 1999; **28**(6): 1200–1205.
 53. Blume PA, Dey HM, Daley LJ, Arrighi JA, Soufer R, Gorecki GA. Diagnosis of pedal osteomyelitis with Tc-99m HMPAO labeled leukocytes. *J Foot Ankle Surg*. 1997; **36**(2): 120–126.
 54. Newman LG, Waller J, Palestro CJ, et al. Leukocyte scanning with 111In is superior to magnetic resonance imaging in diagnosis of clinically unsuspected osteomyelitis in diabetic foot ulcers. *Diabetes Care*. 1992; **15**(11): 1527–30.
 55. Kapoor A, Page S, Lavalley M, Gale DR, Felson DT. Magnetic resonance imaging for diagnosing foot osteomyelitis: a meta-analysis. *Arch Intern Med*. 2007; **167**(2): 125–132.
 56. Craig JG, Amin MB, Wu K, et al. Osteomyelitis of the diabetic foot: MR imaging-pathologic correlation. *Radiology*. 1997; **203**(3): 849–855.
 57. Horowitz JD, Durham JR, Nease DB, Lukens ML, Wright JG, Smead WL. Prospective evaluation of magnetic resonance imaging in the management of acute diabetic foot infections. *Ann Vasc Surg*. 1993; **7**(1): 44–50.

58. Kearney T, Pointin K, Cunningham D, Gedroyc W, Robinson S, Elkeles RS. The detection of pedal osteomyelitis in diabetic patients. *Pract Diabetes Int*. 1999; **16**: 98–100.
59. Ledermann HP, Schweitzer ME, Morrison WB. Nonenhancing tissue on MR imaging of pedal infection: characterization of necrotic tissue and associated limitations for diagnosis of osteomyelitis and abscess. *AJR Am J Roentgenol*. 2002; **178**(1): 215–222.
60. Lipman BT, Collier BD, Carrera GF, et al. Detection of osteomyelitis in the neuropathic foot: nuclear medicine, MRI and conventional radiography. *Clin Nucl Med*. 1998; **23**(2): 77–82.
61. Maas M, Slim EJ, Hoeksma AF, et al. MR imaging of neuropathic feet in leprosy patients with suspected osteomyelitis. *Int J Lepr Other Mycobact Dis* 2002; **70**(2): 97–103.
62. Morrison WB, Schweitzer ME, Batte WG, Radack DP, Russel KM. Osteomyelitis of the foot: relative importance of primary and secondary MR imaging signs. *Radiology*. 1998; **207**(3): 625–632.
63. Nigro ND, Bartynski WS, Grossman SJ, Kruljac S. Clinical impact of magnetic resonance imaging in foot osteomyelitis. *J Am Podiatr Med Assoc*. 1992; **82**(12): 603–615.
64. Remedios D, Valabji J, Oelbaum R, Sharp P, Mitchell R. ^{99m}Tc-nanocolloid scintigraphy for assessing osteomyelitis in diabetic neuropathic feet. *Clin Radiol*. 1998; **53**(2): 120–125.
65. Capriotti G, Chianelli M, Signore A. Nuclear medicine imaging of diabetic foot infection: results of meta-analysis. *Nucl Med Commun*. 2006; **27**(10): 757–764.
66. Devillers A, Moisan A, Hennion F, Garin E, Poirier JY, Bourguet P. Contribution of technetium-99m hexamethylpropylene amine oxime labelled leucocyte scintigraphy to the diagnosis of diabetic foot infection. *Eur J Nucl Med*. 1998; **25**(2): 132–138.
67. Harvey J, Cohen MM. Technetium-99m-labeled leukocytes in diagnosing diabetic osteomyelitis in the foot. *J Foot Ankle Surg*. 1997; **36**(3): 209–214.
68. Palestro CJ, Love C. Nuclear medicine and diabetic foot infections. *Semin Nucl Med*. 2009; **39**(1): 52–65.
69. Unal SN, Birinci H, Baktiroglu S, Cantez S. Comparison of Tc-99m methylene diphosphonate, Tc-99m human immune globulin, and Tc-99m-labeled white blood cell scintigraphy in the diabetic foot. *Clin Nucl Med*. 2001; **26**(12): 1016–1021.
70. Williamson BR, Teates CD, Phillips CD, Croft BY. Computed tomography as a diagnostic aid in diabetic and other problem feet. *Clin Imaging*. 1989; **13**(2): 159–163.
71. Keidar Z, Militianu D, Melamed E, Bar-Shalom R, Israel O. The diabetic foot: initial experience with 18F-FDG PET/CT. *J Nucl Med*. 2005; **46**(3): 444–449.
72. Nawaz A, Torigian DA, Siegelman ES, Basu S, Chrystoskos T, Alavi A. Diagnostic performance of FDG-PET, MRI, and plain film radiography (PFR) for the diagnosis of osteomyelitis in the diabetic foot. *Mol Imaging Biol*. 2010; **12**(3): 335–342.
73. Elamurugan TP, Jagdish S, Kate V, Chandra Parija S. Role of bone biopsy specimen culture in the management of diabetic foot osteomyelitis. *Int J Surg*. 2011; **9**(3): 214–216.
74. Ertugrul MB, Baktiroglu S, Salman S, et al. Pathogens isolated from deep soft tissue and bone in patients with diabetic foot infections. *J Am Podiatr Med Assoc*. 2008; **98**(4): 290–295.
75. Chantelau E, Wolf A, Ozdemir S, Hachmoller A, Ramp U. Bone histomorphology may be unremarkable in diabetes mellitus. *Med Klin (Munich)*. 2007; **102**(6): 429–433.
76. Weiner RD, Viselli SJ, Fulkert KA, Accetta P. Histology versus microbiology for accuracy in identification of osteomyelitis in the diabetic foot. *J Foot Ankle Surg*. 2011; **50**(2): 197–200.
77. Senneville E, Lombart A, Beltrand E, et al. Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study. *Diabetes Care*. 2008; **31**(4): 637–642.
78. Lipsky BA. *Bone of contention: diagnosing diabetic foot osteomyelitis* *Clin Infect Dis*. 2008; **47**(4): 528–530.
79. Lesens O, Desbief F, Vidal M, et al. *Culture of per-wound bone specimens: a simplified approach for the medical management of diabetic foot osteomyelitis* *Clin Microbiol Infect*. 2011; **17**(2): 285–291.
80. Senneville E, Melliez H, Beltrand E, et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. *Clin Infect Dis*. 2006; **42**(1): 57–62.
81. Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. *Diabetes Metab Res*. 2004; **20**(Suppl 1): 90–5.
82. Lipsky BA, Pecoraro RE, Wheat LJ. The diabetic foot. Soft tissue and bone infection. *Infect Dis Clin North Am*. 1990; **4**(3): 409–432.
83. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. *Diabetes Care*. 1998; **21**(5): 855–859.
84. Lipsky BA, Polis AB, Lantz KC, Norquist JM, Abramson MA. The value of a wound score for diabetic foot infections in predicting treatment outcome: a prospective analysis from the SIDE-STEP trial. *Wound Repair Regeneration*. 2009; **17**(5): 671–677.
85. Lipsky BA, Tabak YP, Johannes RS, Vo L, Hyde L, Weigelt JA. *Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost* *Diabetologia*. 2010; **53**(5): 914–923.
86. Ger R. Newer concepts in the surgical management of lesions of the foot in the patient with diabetes. *Surg Gynecol Obstet*. 1984; **158**(3): 213–215.
87. Wheat LJ, Allen SD, Henry M, et al. Diabetic foot infections. Bacteriologic analysis. *Arch Intern Med*. 1986; **146**(10): 1935–1940.
88. Singh SK, Gupta K, Tiwari S, et al. *Detecting aerobic bacterial diversity in patients with diabetic foot wounds using ERIC-PCR: a preliminary communication* *Int J Low Extrem Wounds*. 2009; **8**(4): 203–208.
89. Dowd SE, Wolcott RD, Sun Y, McKeehan T, Smith E, Rhoads D. Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP). *PLoS One*. 2008; **3**(10): e3326.
90. Pellizzer G, Strazzabosco M, Presi S, et al. *Deep tissue biopsy vs. superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection*. *Diabet Med*. 2001; **18**(10): 822–7.
91. Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. *Arch Intern Med*. 1990; **150**(4): 790–797.
92. Citron DM, Goldstein EJ, Merriam CV, Lipsky BA, Abramson MA. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. *J Clin Microbiol* 2007; **45**(9): 2819–2828.
93. Martínez-Gómez DA, Ramírez-Almagro C, Campillo-Soto A, Morales-Cuenca G, Pagán-Ortiz J, Aguayo-Albasini JL. Diabetic foot infections. Prevalence and antibiotic sensitivity of the causative microorganisms. *Enferm Infecc Microbiol Clin*. 2009; **27**(9): 317–321.
94. Bansal E, Garg A, Bhatia S, Attri AK, Chander J. Spectrum of microbial flora in diabetic foot ulcers. *Indian J Pathol Microbiol*. 2008; **51**(2): 204–208.
95. Yoga R, Khairul A, Sunita K, Suresh C. Bacteriology of diabetic foot lesions. *Med J Malaysia*. 2006; **61**(Suppl A): 14–16.
96. Shakil S, Khan AU. Infected foot ulcers in male and female diabetic patients: a clinico-bioinformative study. *Ann Clin Microbiol Antimicrob*. 2010; **9**: 2.
97. Gerding DN. Foot infections in diabetic patients: the role of anaerobes. *Clin Infect Dis*. 1995; **20**(Suppl 2): S283–S288.
98. Tentolouris N, Jude EB, Smirnov I, Knowles EA, Boulton AJ. Methicillin-resistant *Staphylococcus aureus*: an increasing problem in a diabetic foot clinic. *Diabet Med* 1999; **16**(9): 767–771.
99. Dang CN, Prasad YD, Boulton AJ, Jude EB. Methicillin-resistant *Staphylococcus aureus* in the diabetic foot clinic: a worsening problem. *Diabet Med*. 2003; **20**(2): 159–161.
100. Eleftheriadou I, Tentolouris N, Argiana V, Jude E, Boulton AJ. Methicillin-resistant *Staphylococcus aureus* in diabetic foot infections. *Drugs* 2010; **70**(14): 1785–1797.
101. Lagace-Wiens PR, Ormiston D, Nicolle LE, Hilderman T, Embil J. The diabetic foot clinic: not a significant source for acquisition of methicillin-resistant *Staphylococcus aureus*. *Am J Infect Control* 2009; **37**(7): 587–589.
102. Wagner A, Reike H, Angelkort B. Erfahrungen im Umgang mit hochresistenten Keimen bei Patienten mit

- diabetischem Fuß-Syndrom unter besonderer Berücksichtigung von MRSA-Infektionen. [Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant *Staphylococcus aureus* infections]. *Dtsch Med Wochenschr.* 2001; **126**(48): 1353–1356.
103. Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. *Diabetes Res Clin Pract.* 2008; **80**(3): 344–351.
 104. Bowling FL, Jude EB, Boulton AJ. MRSA and diabetic foot wounds: contaminating or infecting organisms? *Curr Diab Rep.* 2009; **9**(6): 440–444.
 105. Varaiya AY, Dogra JD, Kulkarni MH, Bhalekar PN. Extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in diabetic foot infections. *Indian J Pathol Microbiol.* 2008; **51**(3): 370–372.
 106. Zubair M, Malik A, Ahmad J. Clinico-microbiological study and antimicrobial drug resistance profile of diabetic foot infections in North India. *Foot (Edinb)* 2011; **21**(1): 6–14.
 107. Dowd SE, Delton Hanson J, Rees E, et al. Survey of fungi and yeast in polymicrobial infections in chronic wounds. *J Wound Care* 2011; **20**(1): 40–47.
 108. Lipsky BA. Osteomyelitis of the foot in diabetic patients. *Clin Infect Dis* 1997; **25**(6): 1318–26.
 109. Berendt AR, Lipsky B. Is this bone infected or not? Differentiating neuro-osteoarthropathy from osteomyelitis in the diabetic foot. *Curr Diab Rep.* 2004; **4**(6): 424–429.
 110. Tan JS, Friedman NM, Hazelton-Miller C, Flanagan JP, File TMJ. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? *Clin Infect Dis.* 1996; **23**(2): 286–291.
 111. Faglia E, Clerici G, Caminiti M, Quarantiello A, Gino M, Morabito A. The role of early surgical debridement and revascularization in patients with diabetes and deep foot space abscess: retrospective review of 106 patients with diabetes. *J Foot Ankle Surg.* 2006; **45**(4): 220–226.
 112. Aragón-Sánchez J. Treatment of diabetic foot osteomyelitis: a surgical critique. *Int J Low Extrem Wounds.* 2010; **9**(1): 37–59.
 113. Armstrong DG, Lipsky BA. Diabetic foot infections: stepwise medical and surgical management. *Int Wound J.* 2004; **1**(2): 123–132.
 114. Robson MC, Mannari RJ, Smith PD, Payne WG. Maintenance of wound bacterial balance. *Am J Surg.* 1999; **178**(5): 399–402.
 115. O'Meara SM, Cullum NA, Majid M, Sheldon TA. Systematic review of antimicrobial agents used for chronic wounds. *Br J Surg.* 2001; **88**(1): 4–21.
 116. Chantelau E, Tanudjaja T, Altenhofer F, Ersanli Z, Lacicova S, Metzger C. Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. *Diabet Med.* 1996; **13**(2): 156–159.
 117. Hirschl M, Hirschl AM. Bacterial flora in mal perforant and antimicrobial treatment with ceftriaxone. *Chemotherapy.* 1992; **38**(4): 275–280.
 118. Foster AVM, Bates M, Doxford M, Edmonds ME. Should oral antibiotics be given to “clean” foot ulcers with no cellulitis?. In Abstract International Working Group on the Diabetic Foot. : Noordwijkerhout, Netherlands, 1999.
 119. Majcher-Peszynska J, Sass M, Schipper S, et al. Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. *Eur J Clin Pharmacol* 2011; **67**(2): 135–142.
 120. Kuck EM, Bouter KP, Hoekstra JB, Conemans JM, Diepersloot RJ. Tissue concentrations after a single-dose, orally administered ofloxacin in patients with diabetic foot infections. *Foot Ankle Int.* 1998; **19**(1): 38–40.
 121. Muller M, Brunner M, Hollenstein U, et al. Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients. *Antimicrob Agents Chemother.* 1999; **43**(8): 2056–2058.
 122. Marangos MN, Skoutelis AT, Nightingale CH, et al. Absorption of ciprofloxacin in patients with diabetic gastroparesis. *Antimicrob Agents Chemother.* 1995; **39**(9): 2161–2163.
 123. Raymakers JT, Houben AJ, van dH Tordoir JH, Kitslaar PJ, Schaper NC. The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb. *Diabet Med* 2001; **18**(3): 229–234.
 124. el Sherif el Sarky M. Local intravenous therapy in chronic inflammatory and vascular disorders of the foot. *Int Surg* 1997; **82**(2): 175–181.
 125. de Lalla F, Novelli A, Pellizzer G, Milocchi F, Viola R, Rigon A, Stecca C, Dal Pizzol V, Fallani S, Periti P. Regional and systemic prophylaxis with teicoplanin in monolateral and bilateral total knee replacement procedures: study of pharmacokinetics and tissue penetration. *Antimicrob Agents Chemother* 1993; **37**(12): 2693–2698.
 126. Dorigo B, Cameli AM, Trapani M, Raspanti D, Torri M, Mosconi G. Efficacy of femoral intra-arterial administration of teicoplanin in gram-positive diabetic foot infections. *Angiology.* 1995; **46**(12): 1115–1122.
 127. Connolly JE, Wrobel JS, Anderson RF. Primary closure of infected diabetic foot wounds. A report of closed instillation in 30 cases. *J Am Podiatr Med Assoc.* 2000; **90**(4): 175–182.
 128. Lipsky BA, Hoey C. Topical antimicrobial therapy for treating chronic wounds. *Clin Infect Dis.* 2009; **49**(10): 1541–1549.
 129. Lipsky BA, Holroyd KJ, Zasloff M. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. *Clin Infect Dis.* 2008; **47**(12): 1537–1545.
 130. Vermeulen H, van Hattem JM, Storm-Versloot MN, Ubbink DT. Topical silver for treating infected wounds. *Cochrane Database Syst Rev* 2007; (1): CD005486.
 131. Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H. Topical silver for preventing wound infection. *Cochrane Database Syst Rev.* 2010; (3): CD006478.
 132. Silver dressings—do they work? *Drug Ther Bull* 2010; **48**(4): 38–42.
 133. Roeder B, Van Gils CC, Maling S. Antibiotic beads in the treatment of diabetic pedal osteomyelitis. *J Foot Ankle Surg.* 2000; **39**(2): 124–130.
 134. Yamashita Y, Uchida A, Yamakawa T, Shinto Y, Araki N, Kato K. Treatment of chronic osteomyelitis using calcium hydroxyapatite ceramic implants impregnated with antibiotic. *Int Orthop.* 1998; **22**(4): 247–251.
 135. Barth RE, Vogely HC, Hoepelman AI, Peters EJ. To bead or not to bead? Treatment of osteomyelitis and prosthetic joint associated infections with gentamicin bead chains. *Int J Antimicrob Agents* 2011; **38**(5): 371–375.
 136. Lipsky BA. Evidence-based antibiotic therapy of diabetic foot infections. *FEMS Immunol Med Microbiol.* 1999; **26**(3–4): 267–276.
 137. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. *Lancet.* 2005; **366**(9498): 1695–1703.
 138. Cunha BA. Antibiotic selection for diabetic foot infections: a review. *J Foot Ankle Surg.* 2000; **39**(4): 253–257.
 139. Byren I, Peters EJ, Hoey C, Berendt A, Lipsky BA. *Pharmacotherapy of diabetic foot osteomyelitis Expert Opin Pharmacother.* 2009; **10**(18): 3033–3047.
 140. Ragnarson Tennvall G, Apelqvist J, Eneroth M. Costs of deep foot infections in patients with diabetes mellitus. *Pharmacoeconomics.* 2000; **18**(3): 225–238.
 141. McKinnon PS, Paladino JA, Grayson ML, Gibbons GW, Karchmer AW. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. *Clin Infect Dis* 1997; **24**(1): 57–63.
 142. Jeffcoate WJ, Lipsky BA, Berendt AR, et al. International Working Group on the Diabetic Foot. Unresolved issues in the management of ulcers of the foot in diabetes. *Diabet Med* 2008; **25**(12): 1380–1389.
 143. Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. *Clin Infect Dis.* 1997; **24**(4): 643–648.
 144. Grayson ML, Gibbons GW, Habersham GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. *Clin Infect Dis.* 1994; **18**(5): 683–693.
 145. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. *Clin Infect Dis.* 2004; **38**(1): 17–24.

146. Jones V. Debridement of diabetic foot lesions. *The Diabetic Foot*. 1998; **1**: 88–94.
147. Gershater MA, Londahl M, Nyberg P, *et al.* Complexity of factors related to outcome of neuropathic and neuroischaemic/ischaemic diabetic foot ulcers: a cohort study. *Diabetologia* 2009; **52**(3): 398–407.
148. Venkatesan P, Lawn S, Macfarlane RM, Fletcher EM, Finch RG, Jeffcoate WJ. Conservative management of osteomyelitis in the feet of diabetic patients. *Diabet Med*. 1997; **14**(6): 487–490.
149. Senneville E, Yazdanpanah Y, Cazaubiel M, *et al.* Rifampicin–ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. *J Antimicrob Chemother*. 2001; **48**(6): 927–930.
150. Pittet D, Wyssa B, Herter-Clavel C, Kursteiner K, Vaucher J, Lew PD. Outcome of diabetic foot infections treated conservatively: a retrospective cohort study with long-term follow-up. *Arch Intern Med*. 1999; **159**(8): 851–856.
151. Rod-Fleury T, Dunkel N, Assal M, *et al.* Duration of post-surgical antibiotic therapy for adult chronic osteomyelitis: a single-centre experience. *Int Orthop* 2011; **35**(11): 1725–1731.
152. Cruciani M, Lipsky BA, Mengoli C, de Lalla F. Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections. *Cochrane Database Syst Rev* 2009; (3): CD006810.
153. Goldman RJ. Hyperbaric oxygen therapy for wound healing and limb salvage: a systematic review. *PM R*. 2009; **1**(5): 471–489.
154. Löndahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. *Diabetes Care*. 2010; **33**(5): 998–1003.
155. Gupta AK, Uro M, Cooper EA. Onychomycosis therapy: past, present, future. *J Drugs Dermatol* 2010; **9**(9): 1109–1113.
156. Aragón-Sánchez J, Quintana-Marrero Y, Lázaro-Martínez JL, *et al.* Necrotizing soft-tissue infections in the feet of patients with diabetes: outcome of surgical treatment and factors associated with limb loss and mortality. *Int J Low Extrem Wounds*. 2009; **8**(3): 141–146.
157. Aragón-Sánchez FJ, Cabrera-Galván JJ, Quintana-Marrero Y, *et al.* Outcomes of surgical treatment of diabetic foot osteomyelitis: a series of 185 patients with histopathological confirmation of bone involvement. *Diabetologia*. 2008; **51**(11): 1962–1970.
158. Edmonds M. Double trouble: infection and ischemia in the diabetic foot. *Int J Low Extrem Wounds* 2009; **8**(2): 62–63.
159. Gottrup F. Management of the diabetic foot: surgical and organisational aspects. *Horm Metab Res* 2005; **37**(Suppl 1): 69–75.
160. Hauser CJ. Tissue salvage by mapping of skin surface transcutaneous oxygen tension index. *Arch Surg* 1987; **122**(10): 1128–1130.